VERISEQ™ NIPT SOLUTION V2 + YOU:

Ease, accuracy, and speed are just the beginning.

Expect the extraordinary in prenatal screening with VeriSeq NIPT Solution v2
Deliver ease, accuracy, and speed to your lab with an end-to-end workflow, high accuracy, and low failure rates with VeriSeq NIPT Solution v2.1-3
A valuable choice for today and tomorrow.

Offer a comprehensive menu of prenatal screening options with VeriSeq NIPT Solution v2:

- Trisomy 21, 18, and 13
- Sex chromosome aneuploidies
- Rare autosomal aneuploidies (RAAs)
- Partial duplications and deletions ≥7 Mb for all autosomes

VeriSeq NIPT Solution v2 scales according to your lab’s needs, through customized menu selection for each individual sample and versatile batch options. With a long-lasting partnership committed to your lab’s growth and continued success, together we can shape the future of prenatal testing.
VeriSeq NIPT Solution v2 delivers high accuracy with ≥99.9% sensitivity and specificity.\(^2\) Results that you and your clinicians can trust.

Illumina’s performance is backed by published clinical experience data from over 40,000 samples studied.\(^2,4-6\)

<table>
<thead>
<tr>
<th>Trisomy 21(^2)</th>
<th>Trisomy 18(^2)</th>
<th>Trisomy 13(^2)</th>
<th>RAA(^c2)</th>
<th>Partial duplications and deletions ≥7 Mb(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;99.9%</td>
<td>&gt;99.9%</td>
<td>&gt;99.9%</td>
<td>96.4%</td>
<td>74.1%</td>
</tr>
<tr>
<td>&gt;99.90%</td>
<td>&gt;99.90%</td>
<td>&gt;99.90%</td>
<td>99.80%</td>
<td>99.80%</td>
</tr>
</tbody>
</table>

Fetal sex classification concordance
Cytogenetic results\(^2\)

<table>
<thead>
<tr>
<th>Percent concordant</th>
<th>XX</th>
<th>XY</th>
<th>XO</th>
</tr>
</thead>
<tbody>
<tr>
<td>100%</td>
<td>100%</td>
<td>90.5%</td>
<td></td>
</tr>
<tr>
<td>100%</td>
<td>100%</td>
<td>91.7%</td>
<td></td>
</tr>
</tbody>
</table>

A dynamic fetal fraction measurement means lower failure rates, fewer redraws, trusted results for the clinician, and more answers delivered earlier to expecting families.\(^2\)

a. Basic screen performance is reported for T21, T18, and T13 and excludes 16 samples with known mosaics and 49 samples affected with anomalies for the genome-wide screen only; genome-wide screen performance is reported for RAAs and CNVs.\(^2\)
b. Seven twin pregnancies reported correctly as T21 are not shown in the table.\(^2\)
c. RAA excludes chromosomes 21, 18, and 13.\(^2\)
FOR CLINICIANS AND EXPECTING FAMILIES

Get answers in 26 hours with VeriSeq NIPT Solution v2.³

From sample to result, all it takes is 1 technician and 2 hours of hands-on time to deliver results in about 1 day.

Rest assured that you can report timely prenatal screening results to your clinicians. The dedicated service and support team is available for on-site assistance and phone and email communication when you need it the most.

<table>
<thead>
<tr>
<th></th>
<th>Sample and library preparation</th>
<th>Sequencing</th>
<th>Data analysis and report generation</th>
<th>Total overall time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hands-on time</td>
<td>~2 hours</td>
<td>~15 minutes</td>
<td>N/A</td>
<td>~2.25 hours</td>
</tr>
<tr>
<td>Total time</td>
<td>~8 hours</td>
<td>~14 hours</td>
<td>~4 hours</td>
<td>~26 hours</td>
</tr>
</tbody>
</table>

N/A = not available.
Actual times depend on individual lab practices and may vary; the depiction shown represents a 48-sample workflow.
When you need an NIPT solution that fits easily into your lab.

Choose VeriSeq NIPT Solution v2 for a complete end-to-end IVD system that enables a streamlined workflow:\(^1\):

A simple, easy-to-use, automated prenatal screening solution that easily integrates into your lab's current workflow and flexes with your lab's growing needs. This next-generation, sequencing-based, PCR-free system provides a small footprint and less complexity for the lab.

VeriSeq NIPT Solution v2 scales to fit your lab's needs with:\(^1\):

- Versatile batch options for 24, 48, or 96 samples per run
- Customized menu selections for each sample

IVD=\textit{in vitro} diagnostic.
A workflow that works with you.

**Ease:** A simple, easy-to-use, automated system that seamlessly integrates into your lab’s current workflow and flexes with your lab’s growing needs.¹

**Accuracy:** An in-lab IVD NIPT screening assay solution that delivers high accuracy with ≥99.9% sensitivity and specificity.² Results that you and your clinicians can trust.

**Speed:** Results in approximately 26 hours with only 2 hours of hands-on time means clinicians and their expecting families get answers faster.³
**Intended Use**
The VeriSeq NIPT Solution v2 is an in vitro diagnostic test intended for use as a screening test for the detection of genome-wide fetal genetic anomalies from maternal peripheral whole blood specimens in pregnant women of at least 10 weeks gestation. VeriSeq NIPT Solution v2 uses whole-genome sequencing to detect partial duplications and deletions for all autosomes and aneuploidy status for all chromosomes. The test offers an option to request the reporting of sex chromosome aneuploidy (SCA).

**References:**